Jackson Creek Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Jackson Creek Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-8,446	Closed	-$457K	–	302
2025 Q3	$457K	Sell	8,446 -131	-2%	-$7.49K	0.13%	211
2025 Q2	$471K	Sell	8,577 -4,831	-36%	-$284K	0.13%	231
2025 Q1	$948K	Buy	+13,408	New	+$902K	0.3%	173
2024 Q4	–	Sell	-3,869	Closed	-$272K	–	305
2024 Q3	$272K	Buy	+3,869	New	+$323K	0.08%	274

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Jackson Creek Investment Advisors's BMRN Position: Q4 2025 in Review

Jackson Creek Investment Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 8,446 shares — an estimated $457K sold.

Jackson Creek Investment Advisors first reported a position in BMRN in Q3 2024 and held it in 4 quarters. The position peaked at $948K in Q1 2025. 541 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Jackson Creek Investment Advisors reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Jackson Creek Investment Advisors sold 8,446 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $457K.
Jackson Creek Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q3 2024 and held it in 4 quarters.
Jackson Creek Investment Advisors's BioMarin Pharmaceuticals position peaked at $948K in Q1 2025.
541 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Jackson Creek Investment Advisors's 13F filing for Q4 2025, filed 9 Feb 2026.